Nektar Therapeutics (NASDAQ: NKTR) has unveiled compelling Phase 2b REZOLVE-AD data for its investigational therapy, Rezpegaldesleukin, in patients with moderate-to-severe atopic dermatitis. Over a 16-week treatment period, subjects receiving Rezpegaldesleukin experienced a remarkable average 75 percent reduction in Eczema Area and Severity Index (EASI) scores versus placebo, accompanied by pronounced relief in pruritus (itch) intensity, decreased affected body surface area, and lower overall disease severity scores. Importantly, improvements were observed as early as Week 4, underscoring the agent’s rapid onset of action compared to current biologic and small-molecule standards of care.
Beyond clinical endpoints, Rezpegaldesleukin demonstrated robust, dose-dependent suppression of hallmark inflammatory biomarkers—most notably TARC/CCL17 and IL-19—revealing its novel mechanism of action through expansion and activation of regulatory T cells (Tregs). These immunomodulatory effects address the underlying immune dysregulation in atopic dermatitis rather than merely blocking downstream cytokine signals. Nektar plans to share full REZOLVE-AD findings at major dermatology and immunology conferences throughout 2025, with long-term maintenance and safety data expected in early 2026. As a clinical-stage biotech focused on immune-targeted therapies, Nektar leverages its proprietary cytokine-engineering platform to advance treatments across autoimmune, inflammatory, and oncology indications, positioning Rezpegaldesleukin as a potential best-in-class option for tackling chronic skin inflammation.
Read more from finance.yahoo.com